Events

LiVac was awarded a $10,000 People’s Choice award from Medtronic at AusBiotech’s BiotechTalks webcast, after winning a pitching event as part of the Eureka Live programme.

Antisense Therapeutics (ASX:ANP) has announced the phase 2 trial of its immunomodulatory therapy (ATL1102) for Duchenne Muscular Dystrophy has met its primary endpoint and will now advance to a phase 2b study.

Australian company Nyrada (ASX:NYR) has announced a preclinical pharmacokinetic study of its lead candidate compounds has found they can cross the blood-brain-barrier (BBB) in the intact uninjured animal brain.

Melbourne-based company Genetic Technologies (ASX:GTG) has updated on the development of its genetic test for the COVID-19 virus.

Health minister Greg Hunt has announced an additional $20 million in funding for a range of mental health research projects in response to the COVID-19 pandemic.

The Australian Government has given approval to proceed with the implementation of enhanced transparency measures for prescription medicines, in response to public demand for more information on prescription medicines that are under evaluation.

Noxopharm (ASX:NOX) has lodged a pre-Investigational New Drug (pre-IND) submission with the US FDA for a clinical trial of its Veyonda in patients with COVID-19 infection.

Australian venture capital firm OneVentures has announced the appointment of John Westwater and Kelly Constable to its healthcare team.

Australian medical technology company 4DMedical (formerly known as 4Dx) says it has received clearance from the FDA to market its four-dimensional XV Technology lung imaging product - XV Lung Ventilation Analysis Software.

Australia does not have a comparative advantage in the manufacturing of pharmaceuticals but it could still be a national priority for the federal government, according to industry minister Karen Andrews.

Melbourne-based therapeutic antibody development company Patrys (ASX:PAB) has announced the inventor of the Deoxymab technology platform, Dr James Hansen of the Yale School of Medicine, has been awarded a research grant from the US National Institutes of Health.

ResApp Health (ASX:RAP) says its ResAppDx-EU smartphone-based acute respiratory diagnostic test has been under evaluation at a federal government-funded COVID-19 respiratory clinic in Brisbane for the past month.